Potentially Best-in-Class Logic-Gated Cell Therapy Pipeline
| Product Candidates | Target | Application | Discovery | Preclinical | Early Stage Clinical | Late Stage Clinical | Hightlights |
|---|---|---|---|---|---|---|---|
| Wholly Owned Gene Circuit-Enhanced CAR Cell Therapy Programs for Oncology | |||||||
| SENTI-202 | CD33 and/or FLT3 NOT EMCN |
AML, MDS and other blood cancers | Positive preliminary AML data presented at AACR 2025, including correlative data from patients supporting Logic Gate mechanism of action | ||||
| Undisclosed | Undisclosed | Solid Tumors | Provides multiple expansion opportunities | ||||
| Discovery | Preclinical | Early Stage Clinical | Late Stage Clinical |
Product Candidates: SENTI-202 Target: CD33 and/or FLT3 Application: AML, MDS and other blood cancers | |||
Product Candidates: Undisclosed Target: Undisclosed Application: Solid Tumors | |||